The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Efficacy and Safety of Dabigatran Compared With Warfarin in Relation to Baseline Renal Function in Patients With Atrial Fibrillation: A RE-LY (Randomized Evaluation of Long-term Anticoagulation Therapy) Trial Analysis
Abstract
BACKGROUND: Renal impairment increases the risk of stroke and bleeding in patients with atrial fibrillation. In the Randomized Evaluation of Long-Term Anticoagulant Therapy (RELY) trial, dabigatran, with ≈80% renal elimination, displayed superiority over warfarin for prevention of stroke and systemic embolism in the 150-mg dose and significantly less major bleeding in the 110-mg dose in 18 113 patients with nonvalvular atrial fibrillation. This prespecified study investigated these outcomes in relation to renal function. METHODS AND RESULTS: Glomerular filtration rate was estimated with the Cockcroft-Gault, Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI), and Modification of Diet in Renal Disease (MDRD) equations in all randomized patients with available creatinine at baseline (n=17 951), and cystatin C-based glomerular filtration rate was estimated in a subpopulation with measurements available (n=6190). A glomerular filtration rate ≥80, 50 to <80, and <50 mL/min was estimated in 32.6%, 47.6%, and 19.8% and in 21.6%, 59.6%, and 18.8% of patients based on Cockcroft-Gault and CKD-EPI, respectively. Rates of stroke or systemic embolism, major bleeding, and all-cause mortality increased as renal function decreased. The rates of stroke or systemic embolism were lower with dabigatran 150 mg and similar with 110 mg twice daily compared with warfarin, without significant heterogeneity in subgroups defined by renal function (interaction P>0.1 for all). For the outcome of major bleeding, there were significant interactions between treatment and renal function according to CKD-EPI and MDRD equations, respectively (P<0.05). The relative reduction in major bleeding with either dabigatran dose compared with warfarin was greater in patients with glomerular filtration rate ≥80 mL/min. CONCLUSIONS: The efficacy of both dosages of dabigatran was consistent with the overall trial irrespective of renal function. However, with the CKD-EPI and MDRD equations, both dabigatran dosages displayed significantly lower rates of major bleeding in patients with glomerular filtration rate ≥80 mL/min. CLINICAL TRIAL REGISTRATION URL: http://www.clinicaltrials.gov. Unique identifier: NCT00262600.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Renal clearance”
From 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS (2016) · cites this paper as [425]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A New Equation to Estimate Glomerular Filtration Rate
Levey, A. S., Stevens, L. A., Schmid, C. H., Zhang, Y. (., Castro, A. F., Feldman, H. I., Kusek, J. W., Eggers, P., Van Lente, F., Greene, T., et al. (2009) · Annals of Internal Medicine · doi:10.7326/0003-4819-150-9-200905050-00006 · Cited by 25,603
Dabigatran versus warfarin in patients with atrial fibrillation
Connolly, S. J., Ezekowitz, M. D., Yusuf, S., Eikelboom, J., Oldgren, J., Parekh, A., Pogue, J., Reilly, P. A., Themeles, E., Varrone, J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0905561 · Cited by 11,215
Self-citationRivaroxaban versus warfarin in nonvalvular atrial fibrillation
Patel, M. R., Mahaffey, K. W., Garg, J., Pan, G., Singer, D. E., Hacke, W., Breithardt, G., Halperin, J. L., Hankey, G. J., Piccini, J. P., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1009638 · Cited by 9,430
Apixaban versus warfarin in patients with atrial fibrillation
Granger, C. B., Alexander, J. H., McMurray, J. J. V., Lopes, R. D., Hylek, E. M., Hanna, M., Al-Khalidi, H. R., Ansell, J., Atar, D., Avezum, A., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1107039 · Cited by 8,943
Self-citationGuidelines for the management of atrial fibrillation
Authors/Task Force Members, Camm, A. J., Kirchhof, P. F., Lip, G. Y. H., Schotten, U., Savelieva, I., Ernst, S., Gelder, I. C. V., Al‐Attar, N., Hindricks, G., et al. (2010) · European Heart Journal · doi:10.1093/eurheartj/ehq278 · Cited by 5,924
Levey, A. S., Coresh, J., Greene, T., Stevens, L. A., Zhang, Y., Hendriksen, S. M., Kusek, J. W., & Lente, F. V. (2006) · Annals of Internal Medicine · doi:10.7326/0003-4819-145-4-200608150-00004 · Cited by 5,726
Pisters, R., Lane, D. A., Nieuwlaat, R., de Vos, C. B., Crijns, H. J. G. M., & Lip, G. Y. H. (2010) · CHEST Journal · doi:10.1378/chest.10-0134 · Cited by 4,517
Assessing Kidney Function — Measured and Estimated Glomerular Filtration Rate
Stevens, L. A., Coresh, J., Greene, T., & Levey, A. S. (2006) · New England Journal of Medicine · doi:10.1056/nejmra054415 · Cited by 2,952
Effect of clopidogrel added to aspirin in patients with atrial fibrillation
The ACTIVE Investigators (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0901301 · Cited by 2,102
Levey, A. S., Coresh, J., Greene, T., Marsh, J., Stevens, L. A., Kusek, J. W., & Lente, F. V. (2007) · Clinical Chemistry · doi:10.1373/clinchem.2006.077180 · Cited by 1,854
Flagged first, then by citations
Cited by
Sorted by citations
Hindricks, G., Potpara, T., Dagres, N., Arbelo, E., Bax, J. J., Blomström‐Lundqvist, C., Boriani, G., Castella, M., Dan, G.-A., Dilaveris, P., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehaa612 · Cited by 10,550
Self-citation2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS
Kirchhof, P. F., Benussi, S., Kotecha, D., Ahlsson, A., Atar, D., Casadei, B., Castellà, M., Diener, H., Heidbüchel, H., Hendriks, J., et al. (2016) · EP Europace · doi:10.1093/europace/euw295 · Cited by 6,438
Self-citation2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS
Kirchhof, P., Benussi, S., Kotecha, D., Ahlsson, A., Atar, D., Casadei, B., Castella, M., Diener, H.-C., Heidbuchel, H., Hendriks, J., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw210 · Cited by 6,418
Self-citationSteffel, J., Verhamme, P., Potpara, T. S., Albaladejo, P., Antz, M., Desteghe, L., Haeusler, K. G., Oldgren, J., Reinecke, H., Roldan-Schilling, V., et al. (2018) · European Heart Journal · doi:10.1093/eurheartj/ehy136 · Cited by 2,123
Self-citation2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS
Kirchhof, P., Benussi, S., Kotecha, D., Ahlsson, A., Atar, D., Casadei, B., Castella, M., Diener, H.-C., Heidbuchel, H., Hendriks, J., et al. (2016) · European Journal of Cardio-Thoracic Surgery · doi:10.1093/ejcts/ezw313 · Cited by 1,403
Self-citationHeidbüchel, H., Verhamme, P. B., Alings, M., Antz, M., Diener, H., Hacke, W., Oldgren, J., Sinnaeve, P., Camm, A. J., & Kirchhof, P. F. (2015) · EP Europace · doi:10.1093/europace/euv309 · Cited by 1,129
Self-citationHijazi, Z., Oldgren, J., Lindbäck, J., Alexander, J. H., Connolly, S. J., Eikelboom, J. W., Ezekowitz, M. D., Held, C., Hylek, E. M., Lopes, R. D., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)00741-8 · Cited by 490
Self-citationNielsen, P. B., Skjøth, F., Søgaard, M., Kjældgaard, J. N., Lip, G. Y. H., & Larsen, T. B. (2017) · BMJ · doi:10.1136/bmj.j510 · Cited by 350
Wallentin, L. C., Hijazi, Z., Andersson, U., Alexander, J. H., Caterina, R. D., Hanna, M., Horowitz, J. D., Hylek, E. M., Lópes, R. D., Åsberg, S., et al. (2014) · Circulation · doi:10.1161/circulationaha.114.011204 · Cited by 310
Self-citationImpact of Renal Function on Outcomes With Edoxaban in the ENGAGE AF-TIMI 48 Trial
Bohula, E. A., Giugliano, R. P., Ruff, C. T., Kuder, J., Murphy, S. A., Antman, E. M., & Braunwald, E. (2016) · Circulation · doi:10.1161/circulationaha.116.022361 · Cited by 291
Turakhia, M. P., Blankestijn, P. J., Carrero, J. J., Clase, C. M., Deo, R., Herzog, C. A., Kasner, S. E., PASSMAN, R. S., Pecoits‐Filho, R., Reinecke, H., et al. (2018) · European Heart Journal · doi:10.1093/eurheartj/ehy060 · Cited by 297
Steffel, J., Verhamme, P. B., Potpara, T., Albaladejo, P., Antz, M., Desteghe, L., Hæusler, K. G., Oldgren, J., Reinecke, H., Roldán, V., et al. (2018) · EP Europace · doi:10.1093/europace/euy054 · Cited by 248
Self-citationAndreotti, F., Rocca, B., Husted, S., Ajjan, R., ten Berg, J. M., Cattaneo, M., Collet, J., Caterina, R. D., Fox, K. A. A., Halvorsen, S., et al. (2015) · European Heart Journal · doi:10.1093/eurheartj/ehv304 · Cited by 239
Self-citationChanges in Renal Function in Patients With Atrial Fibrillation
Böhm, M., Ezekowitz, M. D., Connolly, S. J., Eikelboom, J. W., Hohnloser, S. H., Reilly, P. A., Schumacher, H., Brueckmann, M., Schirmer, S. H., Kratz, M. T., et al. (2015) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2015.03.577 · Cited by 230
Self-citationChan, K. E., Giugliano, R. P., Patel, M. R., Abramson, S., Jardine, M., Zhao, S. J., Perkovic, V., Maddux, F. W., & Piccini, J. P. (2016) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2016.02.082 · Cited by 231
Dahal, K. B., Kunwar, S., Rijal, J. P., Schulman, P. M., & Lee, J. (2015) · CHEST Journal · doi:10.1378/chest.15-1719 · Cited by 226
Klijn, C. J. M., Paciaroni, M., Berge, E., Korompoki, E., Kõrv, J., Lal, A., Jukka Putaala, A., & Werring, D. J. (2019) · European Stroke Journal · doi:10.1177/2396987319841187 · Cited by 213
2017 consensus of the Asia Pacific Heart Rhythm Society on stroke prevention in atrial fibrillation
Chiang, C., Okumura, K., Zhang, S., Chao, T., Siu, C., Lim, T. W., Saxena, A., Takahashi, Y., & Teo, W. S. (2017) · Journal of Arrhythmia · doi:10.1016/j.joa.2017.05.004 · Cited by 200
Oral Anticoagulation in Patients With Liver Disease
Qamar, A., Vaduganathan, M., Greenberger, N. J., & Giugliano, R. P. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.03.023 · Cited by 188
Boriani, G., Savelieva, I., Dan, G., Deharo, J., Ferro, C. J., Israel, C. W., Lane, D. A., Manna, G. L., Morton, J. B., Moya‐Mitjans, À., et al. (2015) · EP Europace · doi:10.1093/europace/euv202 · Cited by 187
Anticoagulation in Concomitant Chronic Kidney Disease and Atrial Fibrillation
Kumar, S., Lim, E., Covic, A. C., Verhamme, P. B., Gale, C. P., Camm, A. J., & Goldsmith, D. J. A. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2019.08.1031 · Cited by 182
Hijazi, Z., Hohnloser, S. H., Andersson, U., Alexander, J. H., Hanna, M., Keltai, M., Parkhomenko, A. N., Lopez-Sendon, J. L., Lópes, R. D., Siegbahn, A., et al. (2016) · JAMA Cardiology · doi:10.1001/jamacardio.2016.1170 · Cited by 174
Self-citationFordyce, C. B., Hellkamp, A. S., Lokhnygina, Y. V., Lindner, S. M., Piccini, J. P., Becker, R. C., Berkowitz, S. D., BREITHARDT, G. E., Fox, K. A. A., Mahaffey, K. W., et al. (2016) · Circulation · doi:10.1161/circulationaha.116.021890 · Cited by 171
Guidance for the practical management of warfarin therapy in the treatment of venous thromboembolism
Witt, D. M., Clark, N. P., Kaatz, S., Schnurr, T., & Ansell, J. (2016) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-015-1319-y · Cited by 167
Jacobs, V., May, H. T., Bair, T. L., Crandall, B. G., Cutler, M. J., Day, J. D., Mallender, C. D., Osborn, J. S., Stevens, S. M., Weiss, J. P., et al. (2016) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2016.04.039 · Cited by 163
Novel Risk Markers and Risk Assessments for Cardiovascular Disease
Thomas, M. R., & Lip, G. Y. H. (2017) · Circulation Research · doi:10.1161/circresaha.116.309955 · Cited by 157
2018 Korean Guideline of Atrial Fibrillation Management
Joung, B., Lee, J., Lee, K. H., Kim, T., Choi, E., Lim, W., Kang, K., Uhm, J., Lim, H. E., Park, J., et al. (2018) · Korean Circulation Journal · doi:10.4070/kcj.2018.0339 · Cited by 157
Zirlik, A., & Bode, C. (2016) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-016-1446-0 · Cited by 158
Jun, M., James, M. T., Manns, B. J., Quinn, R. R., Ravani, P., Tonelli, M., Perkovic, V., Winkelmayer, W. C., Ma, Z., Hemmelgarn, B. R., et al. (2015) · BMJ · doi:10.1136/bmj.h246 · Cited by 143
Aulin, J., Siegbahn, A. G., Hijazi, Z., Ezekowitz, M. D., Andersson, U., Connolly, S. J., Huber, K., Reilly, P. A., Wallentin, L. C., & Oldgren, J. (2015) · American Heart Journal · doi:10.1016/j.ahj.2015.09.018 · Cited by 144
Self-citationAtrial Fibrillation and Thromboembolism in Patients With Chronic Kidney Disease
Lau, Y. C., Proietti, M., Guiducci, E., Blann, A. D., & Lip, G. Y. H. (2016) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2016.06.057 · Cited by 145
Eikelboom, J. W., Quinlan, D. J., Hirsh, J., Connolly, S. J., & Weitz, J. I. (2017) · JAMA Cardiology · doi:10.1001/jamacardio.2017.0364 · Cited by 145
Self-citationDiener, H., Aisenberg, J., Ansell, J., Atar, D., BREITHARDT, G. E., Eikelboom, J. W., Ezekowitz, M. D., Granger, C. B., Halperin, J. L., Hohnloser, S. H., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw069 · Cited by 142
Self-citationKimachi, M., Furukawa, T. A., Kimachi, K., Goto, Y., Fukuma, S., & Fukuhara, S. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd011373.pub2 · Cited by 144
Lutz, J., Jurk, K., & Schinzel, H. (2017) · International Journal of Nephrology and Renovascular Disease · doi:10.2147/ijnrd.s105771 · Cited by 132
Use of oral anticoagulants in patients with atrial fibrillation and renal dysfunction
Potpara, T., Ferro, C. J., & Lip, G. Y. H. (2018) · Nature Reviews Nephrology · doi:10.1038/nrneph.2018.19 · Cited by 130
Hijazi, Z., Oldgren, J., Lindbäck, J., Alexander, J. H., Connolly, S. J., Eikelboom, J. W., Ezekowitz, M. D., Held, C., Hylek, E. M., Lópes, R. D., et al. (2017) · European Heart Journal · doi:10.1093/eurheartj/ehx584 · Cited by 122
Self-citationApplication of Biomarkers for Risk Stratification in Patients with Atrial Fibrillation
Hijazi, Z., Oldgren, J., Siegbahn, A. G., & Wallentin, L. C. (2016) · Clinical Chemistry · doi:10.1373/clinchem.2016.255182 · Cited by 104
Self-citationSteffel, J., Verhamme, P. B., Potpara, T., Albaladejo, P., Antz, M., Desteghe, L., Hæusler, K. G., Oldgren, J., Reinecke, H., Roldán, V., et al. (2018) · Kardiologia Polska · doi:10.5603/kp.2018.0180 · Cited by 93
Self-citationEffects of dabigatran according to age in atrial fibrillation
Lauw, M. N., Eikelboom, J. W., Coppens, M., Wallentin, L. C., Yusuf, S., Ezekowitz, M. D., Oldgren, J., Nakamya, J., Wang, J., & Connolly, S. J. (2017) · Heart · doi:10.1136/heartjnl-2016-310358 · Cited by 88
Self-citationGlund, S., Stangier, J., van Ryn, J., Schmohl, M., Moschetti, V., Haazen, W., Smet, M. D., Ganßer, D., Norris, S. H., Lang, B. J., et al. (2016) · Clinical Pharmacokinetics · doi:10.1007/s40262-016-0417-0 · Cited by 88
Self-citationClinical Pharmacology of Oral Anticoagulants in Patients with Kidney Disease
Jain, N., & Reilly, R. F. (2018) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.02170218 · Cited by 94
Harrington, J., Carnicelli, A., Hua, K., Wallentin, L. C., Patel, M. R., Hohnloser, S. H., Giugliano, R. P., Fox, K. A. A., Hijazi, Z., Lópes, R. D., et al. (2023) · Circulation · doi:10.1161/circulationaha.122.062752 · Cited by 92
Self-citationFaraoni, D., Levy, J. H., Albaladejo, P., Samama, C. M., & Périopératoire, A. T. G. D. E. H. (2015) · Critical Care · doi:10.1186/s13054-015-0930-9 · Cited by 87
Munoz, F. D., Gharacholou, S. M., Munger, T. M., Friedman, P. A., Asirvatham, S. J., Packer, D. L., & Noseworthy, P. A. (2015) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2015.09.046 · Cited by 77
Feldberg, J., Patel, P., Farrell, A., Sivarajahkumar, S., Cameron, K., Ma, J., & Battistella, M. (2018) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfy031 · Cited by 81
Andò, G., & Capranzano, P. (2016) · International Journal of Cardiology · doi:10.1016/j.ijcard.2016.11.303 · Cited by 79
Antithrombotic treatment in elderly patients with atrial fibrillation: a practical approach
on behalf of Grupo de trabajo de Riesgo vascular de la, S. E. M. I., Fernández, C. S., Formiga, F., Camafort, M., Rodrigo, J. M. C., Díez‐Manglano, J., Reino, A. P., Tiberio, G., & Mostaza, J. M. (2015) · BMC Cardiovascular Disorders · doi:10.1186/s12872-015-0137-7 · Cited by 75
Shields, A. M., & Lip, G. Y. H. (2015) · Journal of Internal Medicine · doi:10.1111/joim.12360 · Cited by 72
Novel Oral Anticoagulants in Patients With Renal Insufficiency: A Meta-analysis of Randomized Trials
Sardar, P., Chatterjee, S., Herzog, E., Nairooz, R. S., Mukherjee, D., & Halperin, J. L. (2014) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2014.04.015 · Cited by 70
Risk of Thromboembolic Events in Atrial Fibrillation With Chronic Kidney Disease
Zeng, W., Sun, X., Tang, K., Mei, W., Liu, L., Xu, Q., & Cheng, Y. (2014) · Stroke · doi:10.1161/strokeaha.114.006881 · Cited by 69
Providencia, R. A., Marijon, É., Bovéda, S., Barra, S., Narayanan, K., Heuzey, J. L., Gersh, B. J., & Gonçalves, L. M. M. (2014) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2014.05.048 · Cited by 67
Shin, J., Secora, A. M., Alexander, G. C., Inker, L. A., Coresh, J., Chang, A. R., & Grams, M. E. (2018) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.13811217 · Cited by 67
Incident Atrial Fibrillation and the Risk of Stroke in Adults with Chronic Kidney Disease
Carrero, J. J., Trevisan, M., Sood, M. M., Barany, P. F., Xu, H., Evans, M., Friberg, L., & Szummer, K. E. (2018) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.04060318 · Cited by 67
Suzuki, S. S., Otsuka, T., Sagara, K., Semba, H., Kano, H., Matsuno, S., Takai, H., Kato, Y., Uejima, T., Oikawa, Y., et al. (2016) · Circulation Journal · doi:10.1253/circj.cj-15-1237 · Cited by 59
Su, X., Yan, B., Wang, L., Lv, J., Cheng, H., & Chen, Y. (2021) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2021.02.328 · Cited by 54
A systematic review of the efficacy and safety of anticoagulants in advanced chronic kidney disease
Parker, K., Hartemink, J., Saha, A., Mitra, R., Lewis, P. J., Power, A. J., Choudhuri, S., Mitra, S., & Thachil, J. V. (2022) · Journal of Nephrology · doi:10.1007/s40620-022-01413-x · Cited by 61
Chen, H.-Y., Ou, S., Huang, C., Lee, P., Chou, K.-J., Lin, P., & Su, Y. (2021) · Clinical Drug Investigation · doi:10.1007/s40261-021-01016-7 · Cited by 56
Hijazi, Z., Oldgren, J., Andersson, U., Connolly, S. J., Eikelboom, J. W., Ezekowitz, M. D., Reilly, P. A., Yusuf, S., Siegbahn, A., & Wallentin, L. C. (2017) · American Heart Journal · doi:10.1016/j.ahj.2017.06.001 · Cited by 53
Self-citationAnticoagulation in Patients with Chronic Kidney Disease
Elenjickal, E. J., Travlos, C. K., Marques, P. S., & Mavrakanas, T. A. (2023) · American Journal of Nephrology · doi:10.1159/000535546 · Cited by 56
Rivaroxaban Plus Aspirin in Patients With Vascular Disease and Renal Dysfunction
Fox, K. A. A., Eikelboom, J. W., Shestakovska, O., Connolly, S. J., Metsarinne, K. P., & Yusuf, S. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2019.02.048 · Cited by 56
Self-citationOral Anticoagulants Beyond Warfarin
Olie, R. H., Winckers, K., Rocca, B., & Cate, H. T. (2023) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-032823-122811 · Cited by 57
Oral Anticoagulant Therapy in Atrial Fibrillation Patients at High Stroke and Bleeding Risk
Potpara, T., & Lip, G. Y. H. (2015) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2015.07.003 · Cited by 52
On the monitoring of dabigatran treatment in “real life” patients with atrial fibrillation
Skeppholm, M., Hjemdahl, P., Antović, J. P., Muhrbeck, J., Eintrei, J., Rönquist-Nii, Y., Pohanka, A., Beck, O., & Malmström, R. E. (2014) · Thrombosis Research · doi:10.1016/j.thromres.2014.06.016 · Cited by 51
Atrial Fibrillation and Non-cardiovascular Diseases: A Systematic Review
Ferreira, C., Providencia, R. A., Ferreira, M. J., & Gonçalves, L. M. M. (2015) · Arquivos Brasileiros de Cardiologia · doi:10.5935/abc.20150142 · Cited by 57
Wetmore, J. B., Roetker, N. S., Yan, H., Reyes, J. L., & Herzog, C. A. (2020) · Stroke · doi:10.1161/strokeaha.120.028934 · Cited by 50
The use of direct oral anticoagulants in chronic kidney disease
Parker, K., & Thachil, J. V. (2018) · British Journal of Haematology · doi:10.1111/bjh.15564 · Cited by 51
Bleeding Risk of Direct Oral Anticoagulants in Patients With Heart Failure And Atrial Fibrillation
Jackevicius, C. A., Lu, L., Ghaznavi, Z., & Warner, A. L. (2021) · Circulation Cardiovascular Quality and Outcomes · doi:10.1161/circoutcomes.120.007230 · Cited by 49
Oral anticoagulation in patients with chronic kidney disease
Malhotra, K., Ishfaq, M. F., Goyal, N., Katsanos, A. H., Parissis, J., Alexandrov, A. W., Alexandrov, A. V., & Tsivgoulis, G. K. (2019) · Neurology · doi:10.1212/wnl.0000000000007534 · Cited by 53
Lip, G. Y. H., Al‐Khatib, S. M., Cosío, F. G., Banerjee, A., Savelieva, I., Ruskin, J. N., Blendea, D. C., Nattel, S., Bono, J. D., Conroy, J., et al. (2014) · Journal of the American Heart Association · doi:10.1161/jaha.114.001179 · Cited by 48
Dabigatran-Related Nephropathy in a Patient with Undiagnosed IgA Nephropathy
Escoli, R., Santos, P. R., Andrade, S. P., & Carvalho, F. (2015) · Case Reports in Nephrology · doi:10.1155/2015/298261 · Cited by 46
Mechanisms And Management Of Thrombo-Embolism In Atrial Fibrillation.
Violi, F., Pastori, D., & Pignatelli, P. (2014) · Europe PMC (PubMed Central) · doi:10.4022/jafib.1112 · Cited by 45
Lauffenburger, J. C., Rhoney, D. H., Farley, J. F., Gehi, A. K., & Fang, G. (2015) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.1597 · Cited by 43
Renal Function Considerations for Stroke Prevention in Atrial Fibrillation
Fanikos, J. R., Burnett, A., Mahan, C. E., & Dobesh, P. P. (2017) · The American Journal of Medicine · doi:10.1016/j.amjmed.2017.04.015 · Cited by 43
Chin, P. K. L., Wright, D. F. B., Zhang, M., Wallace, M. C., Roberts, R. L., Patterson, D. M., Jensen, B. P., Barclay, M. L., & Begg, E. J. (2014) · Drugs in R&D · doi:10.1007/s40268-014-0045-9 · Cited by 42
Nonvitamin K antagonist oral anticoagulant use in patients with renal impairment
Turpie, A. G. G., Purdham, D. M., & Ciaccia, A. (2017) · Therapeutic Advances in Cardiovascular Disease · doi:10.1177/1753944717714921 · Cited by 41
Kodani, E., Atarashi, H., Inoue, H., Okumura, K., Yamashita, T., Origasa, H., & J-RHYTHM Registry Investigators (2017) · European Heart Journal - Quality of Care and Clinical Outcomes · doi:10.1093/ehjqcco/qcx032 · Cited by 43
Oral Anticoagulation in Patients With End-Stage Kidney Disease on Dialysis and Atrial Fibrillation
Hu, A. H., Niu, J., & Winkelmayer, W. C. (2018) · Seminars in Nephrology · doi:10.1016/j.semnephrol.2018.08.006 · Cited by 42
Costa, F., Valgimigli, M., Steg, P. G., Bhatt, D. L., Hohnloser, S. H., ten Berg, J. M., Miede, C., Nordaby, M., Lip, G. Y. H., Oldgren, J., et al. (2020) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvaa135 · Cited by 41
Self-citationChang, T., Liao, J., Chao, T., Vicera, J. J. B., Lin, C., Tuan, T., Lin, Y., Chang, S., Lo, L., Hu, Y., et al. (2018) · IJC Heart & Vasculature · doi:10.1016/j.ijcha.2018.08.003 · Cited by 38
Rhee, T., Lee, S., Choi, E., Oh, S., & Lip, G. Y. H. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.885548 · Cited by 41
Cardioversion and Risk of Adverse Events with Dabigatran versus Warfarin—A Nationwide Cohort Study
Pallisgaard, J. L., Lindhardt, T. B., Hansen, M. L., Schjerning, A.-M., Olesen, J. B., Stærk, L., Torp-Pedersen, C. T., & Gislason, G. (2015) · PLoS ONE · doi:10.1371/journal.pone.0141377 · Cited by 38
Al‐Khalili, F., Lindström, C., & Benson, L. (2016) · Current Medical Research and Opinion · doi:10.1185/03007995.2016.1142432 · Cited by 37
Bonnemeier, H., Huelsebeck, M., & Kloss, S. (2019) · IJC Heart & Vasculature · doi:10.1016/j.ijcha.2019.100367 · Cited by 35
Delanaye, P., Guerber, F., Scheen, A. J., Ellam, T., Bouquegneau, A., Guergour, D., Mariat, C., & Pottel, H. (2016) · Clinical Pharmacokinetics · doi:10.1007/s40262-016-0434-z · Cited by 35
Oral anticoagulant therapy for older patients with atrial fibrillation: a review of current evidence
Bo, M., Grisoglio, E., Brunetti, E., Falcone, Y., & Marchionni, N. (2017) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2017.03.012 · Cited by 37
Novel oral anticoagulants in patients with chronic kidney disease and atrial fibrillation
Stamellou, E., & Floege, J. (2017) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfx322 · Cited by 36
The Use of Estimated Glomerular Filtration Rate for Dose Adjustment of Medications in the Elderly
Elinder, C., Barany, P. F., & Heimbürger, O. (2014) · Drugs & Aging · doi:10.1007/s40266-014-0187-z · Cited by 35
Lullo, L. D., Ronco, C., Cozzolino, M. G., Russo, D., Russo, L., Iorio, B. R. D., Pascalis, A. D., Bàrbera, V., Galliani, M., Vitaliano, E., et al. (2017) · Thrombosis Research · doi:10.1016/j.thromres.2017.04.027 · Cited by 34
Manzano‐Fernández, S., Cayuelas, J. M. A., Marín, F. R., Orenes‐Piñero, E., Gallego, P., Valdés, M., Vicente, V., Lip, G. Y. H., & Roldán, V. (2014) · Revista Española de Cardiología · doi:10.1016/j.recesp.2014.06.027 · Cited by 33
Manzano‐Fernández, S., Cayuelas, J. M. A., Marín, F. R., Orenes‐Piñero, E., Gallego, P., Valdés, M., Vicente, V., Lip, G. Y. H., & Roldán, V. (2014) · Revista Española de Cardiología (English Edition) · doi:10.1016/j.rec.2014.06.026 · Cited by 33
Hawkins, N. M., Jhund, P. S., Pozzi, A., O’Meara, E., Solomon, S. D., Granger, C. B., Yusuf, S., Pfeffer, M. A., Swedberg, K. B., Petrie, M. C., et al. (2016) · European Journal of Heart Failure · doi:10.1002/ejhf.614 · Cited by 33
Self-citationHsu, J. C., & Freeman, J. V. (2018) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.1024 · Cited by 32
The changing circumstance of atrial fibrillation ‐ progress towards precision medicine
Camm, A. J., Savelieva, I., Potpara, T., Hindriks, G., Pison, L., & Blomström‐Lundqvist, C. (2016) · Journal of Internal Medicine · doi:10.1111/joim.12478 · Cited by 30
Stroke Prevention in Atrial Fibrillation in Patients With Chronic Kidney Disease
Qamar, A., & Bhatt, D. L. (2016) · Circulation · doi:10.1161/circulationaha.115.018549 · Cited by 31
Direct oral anticoagulants in chronic kidney disease: an update
Mavrakanas, T. A., Charytan, D. M., & Winkelmayer, W. C. (2020) · Current Opinion in Nephrology & Hypertension · doi:10.1097/mnh.0000000000000634 · Cited by 34
The Impairment in Kidney Function in the Oral Anticoagulation Era. A Pathophysiological Insight
Scicchitano, P., Tucci, M., Bellino, M. C., Cortese, F., Cecere, A., Palo, M. D., Massari, F., Caldarola, P., Silvestris, F., & Ciccone, M. M. (2020) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-020-07004-x · Cited by 30
Buckley, L. F., Rybak, E., Aldemerdash, A. M., Cheng, J. W. M., & Fanikos, J. R. (2016) · Clinical Cardiology · doi:10.1002/clc.22591 · Cited by 30
Non–Vitamin K Antagonist Oral Anticoagulants in Asian Patients With Supranormal Renal Function
Lee, S., Choi, E., Han, K., Jung, J., Cha, M., Oh, S., & Lip, G. Y. H. (2019) · Stroke · doi:10.1161/strokeaha.118.024264 · Cited by 29
Antithrombotic treatment for stroke prevention in atrial fibrillation: The Asian agenda
Chen, C.-H., Chen, M., Gibbs, H. H., Kwon, S. U., Lo, S. T., On, Y. K., Rosman, A., Suwanwela, N. C., Tan, R., Tirador, L. S., et al. (2015) · International Journal of Cardiology · doi:10.1016/j.ijcard.2015.03.369 · Cited by 28
Metadata
- Authors
- Hijazi, Z., Hohnloser, S. H., Oldgren, J., Andersson, U., Connolly, S. J., Eikelboom, J. W., Ezekowitz, M. D., Reilly, P. A., Siegbahn, A., Yusuf, S., & Wallentin, L.
- Affiliations
- Goethe University Frankfurt (DE)
- ORCID
- Venue
- Circulation
- Published
- 2014-03-04
- Volume
- 129
- Issue
- 9
- Pages
- 961-970
- ISSN
- 0009-7322 (ISSN-L)
- 1524-4539
- OpenAlex
- W2026766534
- Cited by
- 396
- References
- 27
- Citations by year
- 2026: 5 · 2025: 6 · 2024: 20 · 2023: 8 · 2022: 22 · 2021: 34 · 2020: 34 · 2019: 40 · 2018: 59 · 2017: 45 · 2016: 47 · 2015: 48 · 2014: 27
- FWCI
- 27.85
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Circulation (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Atrial Fibrillation Management and Outcomes
- Health Sciences › Medicine › Internal Medicine › Venous Thromboembolism Diagnosis and Management
- Health Sciences › Medicine › Clinical Neurology › Acute Ischemic Stroke Management
- Keywords
- dabigatran, warfarin, atrial fibrillation, renal dysfunction, glomerular filtration rate, stroke prevention, systemic embolism, major bleeding, all-cause mortality, CKD-EPI, MDRD equation, Cockcroft-Gault, cystatin C, non-valvular atrial fibrillation, anticoagulation
- MeSH terms
- Dabigatran, Aged, Aged, 80 and over, Anticoagulants, Atrial Fibrillation, Benzimidazoles, Dose-Response Relationship, Drug, Embolism, Female, Glomerular Filtration Rate, Humans, Kidney, Male, Middle Aged, Models, Biological, Risk Factors, Warfarin, beta-Alanine, Treatment Outcome, Stroke, Internationality
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
